RxDoctor Payments Data

Sarah Bickel

Acute Care · Louisville, KYNPI 1316664410

Payments from drug & device makers

$1,185in general payments, 2019–2025

Across 24 payments — averaging $49.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$329
  • AstraZeneca$193
  • Atricure, Inc.$169
  • Abiomed$136
  • Pfizer$109
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$96
  • plus $153 from 4 others

What the payments were for

  • Food & beverage$1,185100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,185 in reported general payments places this provider in the 75th percentile of 319 acute care providers in Kentucky.

See all acute care providers in Kentucky

Medicare billing

Part B allowed, 2024
$22,949
Medicare patients
131
Services billed
495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndaqelTafamidis Meglumine12$247,620
EntrestoSacubitril/Valsartan106$89,019
EliquisApixaban81$81,397
JardianceEmpagliflozin78$63,176
FarxigaDapagliflozin Propanediol34$34,025
BrilintaTicagrelor24$21,512
Bumetanide123$4,510
Potassium Chloride99$2,296
Metoprolol Succinate181$1,914
Digoxin98$1,665
Midodrine Hcl29$1,247
Amiodarone Hcl49$987
Torsemide46$928
Spironolactone163$690
Atorvastatin Calcium67$647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndaqel, Eliquis$109$329,01893 claims
NovartisEntresto$57$89,019106 claims
AstraZenecaFarxiga, Brilinta$193$55,53658 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 319 acute care providers in Kentucky.

Other acute care in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →